Business Wire

MA-AURIGENE

Del

Aurigene to Present Multiple Programs at the SITC 2018 in Washington D.C. and EORTC-NCI-AACR 2018 in Dublin

Aurigene:

SITC – Nov 7-11, Washington D.C.:

(a) CA-170 - Small molecule oral antagonist of PD-L1/VISTA in Ph-2 (India)
(b) Small molecule oral antagonist of CD47
(c) Small molecule oral antagonist of TIGIT/PD-L1

EORTC-NCI-AACR – Nov 13-16, Dublin:

a. Covalent, highly selective CDK12 inhibitors
b. Degrader of SMARCA2/4
c. Dual antagonists of TIGIT and PD-1 pathways
d. Dual inhibitors of CD73 and A2AR

Details: SITC, Nov 7-11 Washington D.C.

CA-170 Small Molecule Oral Antagonist Targeting PD-L1/VISTA
Title: Phase 2 trial of CA-170, a novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients with advanced solid tumor and Hodgkin lymphoma
Abstract Number: P714
Session Details: Late Breaking
Date & Location: Friday, Nov. 9 from 8 a.m. to 8 p.m. and Saturday, Nov. 10 from 8 a.m. to 8:30 p.m. Hall. E

Small Molecule Oral Antagonist Targeting CD47
Title: Efficacy and safety profile of AU7R-104, a small molecule targeting CD47/SIRPα pathway
Abstract Number: P529
Session Details: Innate Anti-Tumor Immunity (NK cells, monocytes, macrophages, etc.)
Date & Location: Friday, Nov. 9, from 12:45 – 2:15 p.m. and 6:30 – 8 p.m. Hall E

Small Molecule Oral Antagonist Targeting TIGIT/PD-L1 Pathways
Title: An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity
Abstract Number: P694
Session Details: T-cell Checkpoints and Checkpoint Inhibitors
Date & location: Saturday, Nov. 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m. Hall E

More details: https://www.sitcancer.org/2018/abstracts/titles

Details of Poster Presentations at EORTC-NCI-AACR, Nov 13-16, Dublin

Covalent Selective CDK12 Inhibitors
Title: Potent anti-tumor activity correlated with inhibition of DNA damage response genes with highly selective and orally bioavailable CDK12 covalent inhibitors
Poster Session: "Drug Design" on 15 November 2018
Poster Time: Thursday 15 November: 10.00-17.30
Poster Abstract Number: 280
Poster Board Number: PB041

SMARCA2/4 Degraders
Title: In vivo anti-tumor efficacy with a dual degrader of SMARCA2 and SMARCA4
Poster Session: "Molecular Targeted Agents - PART II" on 16 November 2018
Poster Time: Friday 16 November: 10.00-14.00
Poster Abstract Number: 411
Poster Board Number: PB074

Small Molecule Oral Antagonists Targeting TIGIT/PD-L1 Pathways
Title: Oral immune checkpoint antagonists dually targeting TIGIT and PD-1 pathways for cancer therapy
Poster Session: "Immune Checkpoints" on 14 November 2018
Poster Time: Wednesday 14 November: 10:00-17:30
Poster Abstract Number: 230
Poster Board Number: PB081

Dual Inhibitors of CD73 and A2AR
Title: First-in-class dual inhibitors of CD73 and A2AR for effective suppression of the adenosine signaling pathway to improve anti-tumor immunity
Poster Session: "Late Breaking Poster Presentation" on 13-16 November 2018
Poster Time: Tuesday 13 November: 12.00-18.30; Wednesday 14 November: 10.00-17.30;
Thursday 15 November: 10.00-17.30; Friday 16 November: 10.00-14.00
Poster Abstract Number: LBA17
Poster Board Number: PB220

More details: https://www.ecco-org.eu/Events/ENA2018/Scientific-Programme-and-Abstracts

About Aurigene
Aurigene’s Proprietary Programs business is engaged in discovery and clinical development of novel and best-in-class therapies to treat cancer and inflammatory diseases. Aurigene’s pipeline is focused on oral check-point inhibitors, transcriptional CDK inhibitors (CDK7 and CDK12) and protein degraders focused on the chromatin remodeling complex (including SMARCA2/4 degraders). Aurigene’s oral PD-L1/ VISTA antagonist program is currently in Phase 2 (trial initiated by Aurigene in India). Aurigene has initiated a Phase I study for its RORg program for autoimmune diseases in July 2018 and expects to initiate Phase 2 studies by early 2019. Aurigene’s selective CDK7 inhibitor is slated for an IND by Q1 2019 and CDK12 inhibitor by end-2019. More details of our pipeline can be found at: http://www.aurigene.com/proprietary-programs/ .

Contact:

Aurigene Rajshree KT Senior Director Strategic Alliances +91–40–44657777 pr@aurigene.com

Link:

ClickThru

Social Media:

https://www.facebook.com/Aurigene-Discovery-Technologies-152736071453990/?fref=ts&ref=br_tf

Information om Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com